HCPCS Level II code J2323 designates a 1 mg unit of natalizumab for injection, a monoclonal antibody used in specialist-administered biologic therapy. Nationally, accurate coding of J2323 is important for claims processing, therapy management, and consistent reporting of biologic drug utilization across outpatient and infusion settings. This code captures the medication component and is commonly billed by infusion centers, specialty clinics, and hospital outpatient departments.

Key payers addressed in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise summary of what J2323 represents clinically, typical sites of service, and which major payers commonly adjudicate claims for natalizumab injections. The publication outlines common billing considerations, payer coverage patterns, and benchmarks where available. It also provides context on how the code integrates with service lines for infusion of biologic therapies and what to expect in terms of billing workflows.

Data not available in the input is noted where applicable, and the content focuses on national implications rather than state-specific rules.